S&P 500   4,452.72 (+0.08%)
DOW   34,780.18 (+0.04%)
QQQ   371.66 (-0.35%)
AAPL   146.46 (-0.25%)
MSFT   297.59 (-0.66%)
FB   351.47 (+1.59%)
GOOGL   2,836.50 (+0.43%)
TSLA   761.11 (+0.99%)
AMZN   3,405.92 (-0.30%)
NVDA   219.64 (-2.30%)
BABA   145.58 (-3.71%)
NIO   35.47 (-1.50%)
CGC   14.02 (-3.71%)
GE   103.68 (+0.70%)
MU   74.20 (+0.22%)
AMD   105.41 (-0.70%)
T   27.22 (+0.11%)
F   13.87 (+1.17%)
ACB   6.06 (-1.46%)
DIS   175.73 (-0.30%)
PFE   44.00 (-0.43%)
BA   221.82 (+0.33%)
BAC   42.32 (+1.51%)
S&P 500   4,452.72 (+0.08%)
DOW   34,780.18 (+0.04%)
QQQ   371.66 (-0.35%)
AAPL   146.46 (-0.25%)
MSFT   297.59 (-0.66%)
FB   351.47 (+1.59%)
GOOGL   2,836.50 (+0.43%)
TSLA   761.11 (+0.99%)
AMZN   3,405.92 (-0.30%)
NVDA   219.64 (-2.30%)
BABA   145.58 (-3.71%)
NIO   35.47 (-1.50%)
CGC   14.02 (-3.71%)
GE   103.68 (+0.70%)
MU   74.20 (+0.22%)
AMD   105.41 (-0.70%)
T   27.22 (+0.11%)
F   13.87 (+1.17%)
ACB   6.06 (-1.46%)
DIS   175.73 (-0.30%)
PFE   44.00 (-0.43%)
BA   221.82 (+0.33%)
BAC   42.32 (+1.51%)
S&P 500   4,452.72 (+0.08%)
DOW   34,780.18 (+0.04%)
QQQ   371.66 (-0.35%)
AAPL   146.46 (-0.25%)
MSFT   297.59 (-0.66%)
FB   351.47 (+1.59%)
GOOGL   2,836.50 (+0.43%)
TSLA   761.11 (+0.99%)
AMZN   3,405.92 (-0.30%)
NVDA   219.64 (-2.30%)
BABA   145.58 (-3.71%)
NIO   35.47 (-1.50%)
CGC   14.02 (-3.71%)
GE   103.68 (+0.70%)
MU   74.20 (+0.22%)
AMD   105.41 (-0.70%)
T   27.22 (+0.11%)
F   13.87 (+1.17%)
ACB   6.06 (-1.46%)
DIS   175.73 (-0.30%)
PFE   44.00 (-0.43%)
BA   221.82 (+0.33%)
BAC   42.32 (+1.51%)
S&P 500   4,452.72 (+0.08%)
DOW   34,780.18 (+0.04%)
QQQ   371.66 (-0.35%)
AAPL   146.46 (-0.25%)
MSFT   297.59 (-0.66%)
FB   351.47 (+1.59%)
GOOGL   2,836.50 (+0.43%)
TSLA   761.11 (+0.99%)
AMZN   3,405.92 (-0.30%)
NVDA   219.64 (-2.30%)
BABA   145.58 (-3.71%)
NIO   35.47 (-1.50%)
CGC   14.02 (-3.71%)
GE   103.68 (+0.70%)
MU   74.20 (+0.22%)
AMD   105.41 (-0.70%)
T   27.22 (+0.11%)
F   13.87 (+1.17%)
ACB   6.06 (-1.46%)
DIS   175.73 (-0.30%)
PFE   44.00 (-0.43%)
BA   221.82 (+0.33%)
BAC   42.32 (+1.51%)
ASX:MSB

Mesoblast Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume10.19 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive MSB News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.


About Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mesoblast (ASX:MSB) Frequently Asked Questions

What stocks does MarketBeat like better than Mesoblast?

Wall Street analysts have given Mesoblast a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mesoblast wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Thursday, November 18th 2021.
View our earnings forecast for Mesoblast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (ASX:MSB) released its quarterly earnings results on Thursday, February, 21st. The company reported ($0.09) earnings per share for the quarter.
View Mesoblast's earnings history
.

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 64, Pay $1.67M)
  • Mr. Josh Muntner BFA, M.B.A., Chief Financial Officer (Age 52, Pay $934.84k)
  • Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 53)
  • Mr. Michael Schuster M.B.A., MS, BSc, MBA, Head of Pharma Partnering (Age 44)
  • Dr. Eric Strati M.B.A., Ph.D., Pharm.D., MBA, Sr. VP of Commercial
  • Dr. Fred Grossman, Chief Medical Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S., Chief Operating Officer (Age 57)
  • Sir Jonathan Richard Symonds CBE, BA, FCA, Head of Corp. Fin. & Strategy (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Dr. Paul J. Simmons BSc, Ph.D., Head of Research & New Product Devel. (Age 62)

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Genfit (GNFT), Pluristem Therapeutics (PSTI), Starpharma (SPL), Viking Therapeutics (VKTX), Alkane Resources (ALK) and Alcidion Group (ALC).

What is Mesoblast's stock symbol?

Mesoblast trades on the ASX under the ticker symbol "MSB."

How much money does Mesoblast make?

Mesoblast has a market capitalization of $0.00 and generates $7.46 million in revenue each year.

How many employees does Mesoblast have?

Mesoblast employs 102 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

Where are Mesoblast's headquarters?

How can I contact Mesoblast?

Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.